Our previous and current data show that adiponectin levels are associated with the risk of future development of RA in patients with overweight/obesity, thus supporting the hypothesis that this adipokine might play a role in the pathogenesis of RA at least in this group of patients. Here, ADIPOQ is linked to rheumatoid arthritis.